Isatuximab for relapsed or hard-to-treat T-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called isatuximab for people with a type of leukemia (T-cell acute lymphoblastic leukemia) that has come back after treatment or that did not go away. Isatuximab targets a protein on the leukemia cells, which might help the immune system fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have T-ALL or T-LBL that has come back after treatment, or that did not get better with at least three rounds of chemotherapy.
- You have leukemia cells that show a protein called CD38 (this is usually tested on a biopsy).
- You are in generally good health (able to do daily activities, with some limitations).
- You have adequate liver and kidney function.
- You can attend study visits and follow the treatment plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests whether adding targeted drugs to standard chemotherapy works better for adults newly diagnosed with T-ALL. If you have not had any prior treatment for leukemia, this study might be an option.
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
This trial tests a new type of immune therapy—called CD5-targeting CAR T-cells—for people with a hard-to-treat form of T-cell acute lymphoblastic leukemia. It aims to see if these specially designed cells can find and destroy leukemia cells with the CD5 marker.
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
Hear when a new T-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.